Intended for healthcare professionals


Seven days in medicine: 2-8 November 2022

BMJ 2022; 379 doi: (Published 10 November 2022) Cite this as: BMJ 2022;379:o2682


Pfizer and BioNTech test covid and flu vaccine

The drug manufacturers Pfizer and BioNTech have begun trialling a combined covid-19 and influenza vaccine. The single dose vaccine, which brings together the companies’ omicron specific vaccine and mRNA based flu shot, is set to be tested in 180 volunteers aged 18-64 in the US. It is being evaluated on safety, tolerability, and immunogenicity. Ugur Sahin, chief executive officer and cofounder of BioNTech, said, “The data will also provide us with more insights on the potential of mRNA vaccines addressing more than one pathogen. This will help us to further develop our infectious disease pipeline to deliver on patient-centric vaccination approaches.”1

Asian patients in England lost out in elective care

During the first year of the covid pandemic people of Asian ethnic backgrounds in England experienced a 49% fall in the number of elective procedures undertaken (equivalent to 23 000 missed procedures), which compared with a 44% drop among white and black groups (17 000 missed procedures). The largest variation was seen in cardiac care, where procedures fell by 45% in the Asian group, 35% in the black group, and 28% in the white group. Reasons included epidemiology, deprivation, trust in health services and the government, and the shift to digital care, found an analysis by the Nuffield Trust and the NHS Race and Health Observatory. …

View Full Text

Log in

Log in through your institution


* For online subscription